Exosomes-Coated miR-34a Displays Potent Antitumor Activity in Pancreatic Cancer Both in vitro and in vivo.
Ling ZuoHongyu TaoHuanli XuCong LiGan QiaoMingyue GuoShousong CaoMinghua LiuXiukun LinPublished in: Drug design, development and therapy (2020)
ExomiR-34a can inhibit the growth of pancreatic cancer both in vitro and in vivo. Targeting miR-34a is a promising strategy for the treatment of pancreatic cancer. ExomiR-34a has the potential to be developed as a novel anticancer agent for the treatment of human pancreatic malignancy.